While i'd agreed the trial isn't over the MOS has, to first order, been reached. It'll bounce around a little - but it would be just as likely to shrink somewhat as grow somewhat.
PS and FWIW - the overall HR for this 2nd line nsclc trial roughly matches the ratio of medians which is better than I (and others) expected. But the key downside is that they didn't release trial balance data or the xmas tree plot (particularly the Eastern European and Indian data vs ROW.
Market Data 
Markets 
AI
